Document Detail

Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model.
MedLine Citation:
PMID:  18589385     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recombinant human erythropoietin (rhEPO) is used for the treatment of anemia of prematurity. However, it has also been found to have properties similar to vascular endothelial growth factor (VEGF), the major angiogenic factor implicated in the pathogenesis of retinopathy of prematurity (ROP). We sought to determine whether rhEPO is an independent risk factor for the development of ROP. METHODS: Data were analyzed from 264 infants admitted to the Loma Linda University Children's Hospital neonatal intensive care unit in 1994 and 2002. The data included demographic characteristics, incidence of major morbidities, rhEPO treatment, number of red blood cell transfusions received, and incidence and severity of ROP. A multiple logistic regression model was used to determine the relation of the studied risk factors to the incidence (any stage) and severity (threshold ROP requiring cryotherapy or laser photocoagulation) of ROP. RESULTS: The risk of developing ROP increased among infants who received >20 doses of rhEPO was higher compared with those who received < or =20 doses (OR, 3.53; 95% CI, 1.59, 7.85). These infants were also more likely to require laser photocoagulation (OR, 4.31; 95% CI, 1.99, 9.33). The age at which rhEPO was started was also a significant risk factor, with those starting rhEPO after 20 days of age having almost fourfold the risk of ROP compared with those starting it on or before 20 days of age (OR, 3.57; 95% CI, 1.59, 8.03). CONCLUSIONS: rhEPO was found to be a significant independent risk factor for the development of ROP.
Kevin K Suk; Jennifer A Dunbar; Anthony Liu; Noha S Daher; Cheri K Leng; Jason K Leng; Pauline Lim; Samantha Weller; Elba Fayard
Related Documents :
3838825 - The retinopathy of prematurity: medicolegal aspects.
9345615 - Testing for interaction between maternal smoking and tgfa genotype among oral cleft cas...
18334945 - Endothelial nitric oxide synthase gene t-786c and 27-bp repeat gene polymorphisms in re...
20858135 - Long-term effects of presurgical infant orthopedics in patients with cleft lip and pala...
16109465 - Catch-up growth in malawian babies, a longitudinal study of normal and low birthweight ...
7338335 - Infant socialization and maternal influence in chimpanzees.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus     Volume:  12     ISSN:  1528-3933     ISO Abbreviation:  J AAPOS     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-30     Completed Date:  2008-11-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9710011     Medline TA:  J AAPOS     Country:  United States    
Other Details:
Languages:  eng     Pagination:  233-8     Citation Subset:  IM    
Loma Linda University, School of Medicine, Loma Linda, California 92354, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Anemia, Neonatal / drug therapy
Birth Weight
California / epidemiology
Dose-Response Relationship, Drug
Erythropoietin, Recombinant / administration & dosage,  adverse effects*
Follow-Up Studies
Infant, Newborn
Models, Statistical*
Regression Analysis
Retinopathy of Prematurity / epidemiology*,  etiology*
Retrospective Studies
Risk Factors
Reg. No./Substance:
0/Erythropoietin, Recombinant
Comment In:
J AAPOS. 2008 Jun;12(3):221-2   [PMID:  18396079 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prophylactic antibiotic use: hardwiring of physician behavior, not education, leads to compliance.
Next Document:  Phakic intraocular lens correction of high ametropia in children with neurobehavioral disorders.